In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LuMend Inc.

Division of Cardinal Health Inc./Cordis Corp.
www.lumend.com

Latest From LuMend Inc.

Total Occlusions: Device Obstacle or Opportunity?

The market is promising for using catheters, instead of surgery, to open vascular blockages. But the right technology remains elusive.
Medical Device Clinical Trials

De Novo's Device Strategy Pays Off, Others May Follow

De Novo Ventures, having successfully closed on its second fund, appears to be succeeding with a contrarian investment strategy that not only is dedicated to life sciences, but includes a strong commitment to medical devices.
Business Strategies Innovation

Abbott Vascular: The Now-Ready-For-Prime-Time Player

Four years ago, lured into a mainstream cardiovascular business by the promise of drug-eluting stents, Abbott set about revamping its medical products business in an effort to create a device business that would rival its pharmaceutical business in financial returns. What was at first a niche strategy, aimed at bringing small, but interesting technologies to interventionalists, has become a more broad-based play that, company officials hope, will place them among the leaders in vascular devices.
Medical Device Business Strategies

Fair Winds or Foul in Treating Total Occlusions?

The company that did the largest private financing last years was, surprisingly, Wilmington, MA-based OmniSonics Medical Technologies. The company is developing an innovative technology that uses acoustical energy to break up clots, plaques, and other occlusions wherever they occur in the human vasculature. OmniSonics' Series C financing will ultimately wind up raising a total of $44 million. The company's first approval, expected later this year, will come in treating peripheral disease, but the golden ring is clearly coronary arteries and that includes chronic total occlusions, a challenge that has been particularly vexing for both interventional cardiologists and medical device developers. Indeed, the recent news that CTO start-up Lumend Inc. is significantly scaling back its operations is a case in point.
Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Cardinal Health Inc.
  • Senior Management
  • Timothy D Kahlenberg, Pres.
    Kurt D Sparks, VP, R&D
    Steve J Moscaret, VP, Sales & Mktg.
  • Contact Info
  • LuMend Inc.
    Phone: (650) 364-1400
    400 Chesapeake Dr.
    Redwood City, CA 94063
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register